The study identified a higher risk of second line ART failure among patients who had poor level of ART drug adherence, advanced WHO clinical stage at switch, CD4 count <100 cells/mm3 at switch and presence of tuberculosis co-infection. Here, CD4 is linked to tuberculosis.